-
Carl Icahn's Track Record In Big Pharma
Friday, February 24, 2017 - 10:40am | 1192Read More...Billionaire investor and corporate raider Carl Icahn has trained his eyes on Bristol-Myers Squibb Co (NYSE: BMY). A Wall Street Journal report revealed on Tuesday that Icahn has picked up a substantial stake in the pharma giant, although the report did not put a number to it. Does Icahn's...
-
Citi Lowers Genzyme (GENZ) Price Target
Wednesday, June 30, 2010 - 10:29am | 284Read More...Citi Investment Research & Analysis analyst Yaron Werber maintained a Buy/High Risk rating for shares of Genzyme Corporation (Nasdaq: GENZ), while lowering the stock's price target to $64 per share, down from the previous price target of $66. Werber said that Genzyme (GENZ) announced further (...
